I am pleased to be moderating the Industry Leaders Fireside Chat on day one of the Cell & Gene Therapy Regulatory Affairs Summit in Washington, DC on October 29-30.  We will be discussing the most pressing challenges facing this critical sector of the drug development industry, as well as the future of the field.  Key topics will include looking at cross-border regulatory challenges, obstacles sponsors face when transitioning into a pivotal Phase 3 clinical trial, and the use of advanced technologies such as artificial intelligence to drive cell and gene therapy target identification and product development.  My esteemed panelists include Sean Russell from Achilles Therapeutics, Fubao Wang from Prime Medicine, and Jean-Philippe Combal from Vivet Therapeutics. 

Stay tuned for a follow-up post after the conference where I will recap what will certainly be a robust discussion about the current and future state of the cell & gene therapy industry.